Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Acute cardiovascular and hormonal effects of GH and

Clinical Trial . 1999 Apr;22(4):266-72. doi: 10.1007/BF03343555. V Podio, M R Valetto, F Broglio, G Bertuccio, G Del Rio, E Arvat, M F Boghen, R Deghenghi, G Muccioli, H Ong, E Ghigo Affiliations PMID: 10342360 DOI: 10.1007/BF03343555 Clinical Trial Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans G Bisi et al. J Endocrinol Invest. 1999 Apr. Abstract Reduced cardiac mass and performances are present in GH deficiency and are counteracted by rhGH replacement. GH and IGF-I possess specific myocardial receptors and have been reported able to exert an acute inotropic effect. Synthetic GH secretagogues (GHS) possess specific pituitary and hypothalamic but even myocardial receptors. In 7 male volunteers, we studied cardiac performance by radionuclide angiocardiography after iv administration of rhGH or hexarelin (HEX), a peptidyl GHS. The administration of rhGH or HEX increased circulating GH levels to the same extent (AUC: 1594.6+/-88

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Clinical Trial

. 1999 Apr;22(4):266-72.

doi: 10.1007/BF03343555.

V Podio, M R Valetto, F Broglio, G Bertuccio, G Del Rio, E Arvat, M F Boghen, R Deghenghi, G Muccioli, H Ong, E Ghigo

Affiliations

PMID: 10342360 DOI: 10.1007/BF03343555

Clinical Trial

Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans

G Bisi et al. J Endocrinol Invest. 1999 Apr.

Abstract

Reduced cardiac mass and performances are present in GH deficiency and are counteracted by rhGH replacement. GH and IGF-I possess specific myocardial receptors and have been reported able to exert an acute inotropic effect. Synthetic GH secretagogues (GHS) possess specific pituitary and hypothalamic but even myocardial receptors. In 7 male volunteers, we studied cardiac performance by radionuclide angiocardiography after iv administration of rhGH or hexarelin (HEX), a peptidyl GHS. The administration of rhGH or HEX increased circulating GH levels to the same extent (AUC: 1594.6+/-88.1 vs 1739.3+/-262.2 microg/l/min for 90 min) while aldosterone and catecholamine levels did not change; HEX, but not rhGH, significantly increased cortisol levels. Left ventricular ejection fraction (LVEF), mean blood pressure (MBP) and heart rate (HR) were unaffected by rhGH (62.4+/-2.1 vs 62.1+/-2.3%, 90.6+/-3.4 vs 92.0+/-2.5 mm Hg, 62.3+/-1.8 vs 66.7+/-2.7 bpm). HEX increased LVEF (70.7+/-3.0 vs 64.0+/-1.5%, p<0.03) without significant changes in MBP and HR (92.8+/-4.7 vs 92.4+/-3.2 mm Hg, 63.1+/-2.1 vs 67.0+/-2.9 bpm). LVEF significantly raised at 15 min, peaked at 30 min and lasted up to 60 min after HEX. These findings suggest that in man, the acute administration of Hexarelin exerts a short-lasting, positive inotropic effect. This effect seems GH-independent and might be mediated by specific GHS myocardial receptors.

PubMed Disclaimer

References

Lancet. 1998 Apr 25;351(9111):1233-7 - PubMed

J Cardiovasc Pharmacol. 1998 Aug;32(2):260-5 - PubMed

Eur J Endocrinol. 1997 May;136(5):445-60 - PubMed

Circulation. 1982 Jan;65(1):82-91 - PubMed

Endocrinology. 2000 Jan;141(1):60-6 - PubMed

Connected topics

Follow this recovery question